Table 1.

Direct-acting antiviral pharmaceuticals against HCV infection approved for use in interferon-free therapy within the EU.

Substance class	Generic substance	Brand name	Genotype specificity	Barrier to resistence
NS5B polymerase inhibitor (nucleotide analogue)	Sofosbuvir	Sovaldi	High activity against genotype 1–6	Very high
		Harvoni
NS5B polymerase inhibitor (non-nucleotide analogue)	Dasabuvir	Exviera	Relevant activity only for genotype 1	Low
NS3/4A protease inhibitor	Simeprevir	Olysio	High activity against genotype 1 and 4 No activity against genotype 3	Low
NS3/4A protease inhibitor	Paritaprevir	Viekirax	High activity against genotype 1 and 4	Low
NS5A inhibitor	Daclatasvir	Daklinza	High activity against genotype 1 and 4 Clinical relevant activity also against other genotypes	Low
NS5A inhibitor	Ledipasvir	Harvoni	High activity against genotype 1 and 4 Clinical relevant activity also against genotypes 3–6	Low
NS5A inhibitor	Ombitasvir	Viekirax	High activity against genotype 1 and 4	Low